Download App

Log in to access Online Inquiry
Company Overview More
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
CEO: Kapusta, Matthew Craig
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

QURE uniQure NV
13.720+0.310+2.31%
Post Mkt Price
13.72000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Assets
Current assets
Cash, cash equivalents and short term investments
101.25% 524.89M 127.11% 556.26M 127.11% 556.26M 106.97% 578.46M
-Cash and cash equivalents
101.25% 524.89M 127.11% 556.26M 127.11% 556.26M 106.97% 578.46M
Receivables
609.72% 38.64M 788% 58.77M 788% 58.77M 1.4% 3.77M
-Accounts receivable
609.72% 38.64M 788% 58.77M 788% 58.77M 1591.03% 3.77M
Prepaid assets
35.23% 12.42M 143.03% 10.54M 143.03% 10.54M 148.2% 10.35M
Other current assets
-67.18% 2.26M -11.54% 2.68M -11.54% 2.68M -- 1.18M
Total current assets
104.8% 578.21M 142.65% 628.24M 142.65% 628.24M 106.61% 593.76M
Non current assets
Net PPE
18.05% 69.86M 18.26% 69.08M 18.26% 69.08M 20.71% 67.41M
-Gross PPE
13.97% 108.36M 13.18% 105.98M 13.18% 105.98M 16.02% 103.31M
-Accumulated depreciation
-7.24% -38.5M -4.75% -36.9M -4.75% -36.9M -8.13% -35.9M
Goodwill and other intangible assets
2459.84% 87.7M 2214.09% 90.32M 2214.09% 90.32M 1914.55% 92.07M
-Goodwill
5028.38% 26.57M 4998.34% 27.63M 4998.34% 27.63M 5316.99% 28.06M
-Other intangible assets
2002.3% 61.14M 1765.1% 62.69M 1765.1% 62.69M 1479.59% 64.01M
Non current deferred assets
-4.71% 15.44M -4.7% 15.65M -4.7% 15.65M -- 15.72M
Other non current assets
118.59% 5.94M 114.59% 5.9M 114.59% 5.9M 108.84% 5.67M
Total non current assets
119.49% 178.94M 122.06% 180.94M 122.06% 180.94M 186.5% 180.86M
Total assets
108.09% 757.15M 137.72% 809.18M 137.72% 809.18M 121% 774.63M
Liabilities
Current liabilities
Payables
72.55% 9.92M -33.67% 2.5M -33.67% 2.5M 128.83% 5.37M
-accounts payable
72.55% 9.92M -33.67% 2.5M -33.67% 2.5M 128.83% 5.37M
Current accrued expenses
25.47% 19.95M 78.53% 28.49M 78.53% 28.49M 72.89% 30.75M
Current debt and capital lease obligation
5.44% 5.75M 4.53% 5.77M 4.53% 5.77M 4.43% 5.8M
-Current capital lease obligation
5.44% 5.75M 4.53% 5.77M 4.53% 5.77M 4.43% 5.8M
Current deferred liabilities
-- -- -- 0 -- 0 -- 0
Other current liabilities
-- 9.08M -- -- -- -- -- --
Current liabilities
39.24% 44.7M 34.5% 36.76M 34.5% 36.76M 25.69% 41.92M
Non current liabilities
Long term debt and capital lease obligation
29.71% 129.65M 96.83% 129.95M 96.83% 129.95M 53.77% 101.22M
-Long term debt
43.93% 101.42M 183.47% 100.96M 183.47% 100.96M 101.41% 71.49M
-Long term capital lease obligation
-4.26% 28.23M -4.66% 28.99M -4.66% 28.99M -1.98% 29.73M
Non current deferred liabilities
-- 11.3M -- 12.91M -- 12.91M -41.37% 13.14M
Other non current liabilities
720.66% 25.5M 977.1% 33.78M 977.1% 33.78M 5683.86% 27.59M
Total non current liabilities
61.51% 166.45M 155.42% 176.64M 155.42% 176.64M 59.03% 141.95M
Total liabilities
56.22% 211.15M 121.17% 213.4M 121.17% 213.4M 49.96% 183.87M
Shareholders'equity
Share capital
1.47% 2.82M 3.36% 2.8M 3.36% 2.8M 3.82% 2.8M
-common stock
1.47% 2.82M 3.36% 2.8M 3.36% 2.8M 3.82% 2.8M
Retained earnings
39.27% -501.82M 42% -455.14M 42% -455.14M 40.9% -463.35M
Paid-in capital
3.28% 1.08B 6% 1.08B 6% 1.08B 6.19% 1.07B
Gains losses not affecting retained earnings
-1774.73% -39.31M -391.27% -28.86M -391.27% -28.86M -866.52% -17.88M
Total stockholders'equity
138.75% 546M 144.27% 595.78M 144.27% 595.78M 159.22% 590.76M
Total equity
138.75% 546M 144.27% 595.78M 144.27% 595.78M 159.22% 590.76M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
--Unqualified Opinion----

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%